All In Biotech

Drug Trial Radar · NCT07223814

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

Bleximenib or Placebo in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for the Treatment of Patients With Newly Diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: a Double-blind Phase 3 Study

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 875 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

875

Planned (sponsor's estimate)

Start

Mar 1, 2026

Primary completion

Jun 2030

Study completion Dec 2033

Sponsor

Lead sponsor
Stichting Hemato-Oncologie voor Volwassenen NederlandAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
German-Austrian Acute Myeloid Leukemia Study Group
First posted
Nov 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The current standard of care treatment for adult patients with acute myeloid leukemia (AML) consists of chemotherapy and, if indicated, donor stem cell transplantation. Bleximenib blocks the interaction between a protein called menin and another protein called KMT2A in the leukemia cells. When this interaction is disrupted in AML with mutations in the NPM1 or KMT2A gene, bleximenib can cause leukemia cells to die. The main objective is to assess if treatment with bleximenib, when added to chemotherapy treatment will improve treatment outcome in adult participants with newly diagnosed AML who present with mutations in the NPM1 or KMT2A genes. This is a randomized, double-blind, placebo-controlled, phase 3 clinical trial. All of the participants will receive standard chemotherapy treatment, combined with either bleximenib or a placebo. A placebo is a substance that looks like the study medicine but has no active ingredients (e.g., a sugar pill). In a double blind trial neither the participant nor the doctor know if placebo or active study drug is given. After the end of the protocol treatment there will be an observational follow-up of 4 years from the time of inclusion of the last patient. The results of the different treatment groups will be compared. 875 previously untreated patients with AML with a specific change in the DNA of the leukemia cells (a KMT2A rearrangement or a NPM1 mutation) will be included. Participants must be 18 years or older and considered eligible for intensive chemotherapy.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • BleximenibDrug

    Participants will receive bleximenib

  • CytarabineDrug

    Participants will receive Cytarabine

  • Daunorubicin or IdarubicinDrug

    Participants will receive Daunorubicin or Idarubicin

  • PlaceboDrug

    Participants will receive Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-Free Survival (EFS) in adult patients with newly diagnosed NPM1m or KMT2Ar AML eligible for intensive chemotherapyTime frame: Up to 4 years and 5 months

Locations

108 sites in 13 countries. Site status is shown where the registry gives one.

  • US-Los Angeles CA-UCLA

    Los Angeles, California · Recruiting

  • US-San Francisco CA-UCSF

    San Francisco, California · Recruiting

  • US-Orlando FL-ORLANDOHEALTH

    Orlando, Florida · Recruiting

  • US-Atlanta GA-EMORY

    Atlanta, Georgia · Recruiting

  • US-Chigago IL-UHCHICAGO

    Chicago, Illinois · Recruiting

  • US-Kansas City KS-KUMC

    Kansas City, Kansas · Recruiting

  • US-Baltimore MD-UMGCCC

    Baltimore, Maryland · Recruiting

  • US-St Louis MO-WASHU

    St Louis, Missouri · Recruiting

  • US-Charlotte NC-NOVANTCHARLOTTE

    Charlotte, North Carolina · Recruiting

  • US-Winston-Salem NC-NOVANTWINSTON

    Winston-Salem, North Carolina · Recruiting

  • US-Cincinnati OH-CINCY

    Cincinnati, Ohio · Recruiting

  • US-Colombus OH-OSU

    Columbus, Ohio · Recruiting

  • US-Pittsburgh PA-PITT

    Pittsburgh, Pennsylvania · Recruiting

  • AU-Adelaide-FLINDERS

    Adelaide, Australia · Recruiting

  • AU-Adelaide-RAH

    Adelaide, Australia · Recruiting

  • AU-Birtinya-SUNSHINECOAST

    Birtinya, Australia · Recruiting

  • AU-Brisbane-PAH

    Brisbane, Australia · Recruiting

  • AU-Brisbane-RBWH

    Brisbane, Australia · Recruiting

  • AU-Camperdown-RPA

    Camperdown, Australia · Recruiting

  • AU-Melbourne-AUSTIN

    Melbourne, Australia · Recruiting

  • AU-Melbourne-MONASH

    Melbourne, Australia · Recruiting

  • AU-Melbourne-PMCC

    Melbourne, Australia · Recruiting

  • AU-Sydney-RNSH

    Sydney, Australia · Recruiting

  • AU-Sydney-WSAH

    Sydney, Australia · Recruiting

  • AT-Feldkirch-IKHF

    Feldkirch, Austria · Recruiting

  • AT-Linz-ORDENSKLINIKUM

    Linz, Austria · Recruiting

  • BE-Antwerpen-UZA

    Antwerp, Belgium · Recruiting

  • BE-Antwerpen-ZAS

    Antwerp, Belgium · Recruiting

  • BE-Brugge-AZBRUGGE

    Bruges, Belgium · Recruiting

  • BE-Brussel-BORDET

    Brussels, Belgium · Recruiting

  • BE-Bruxelles-STLUC

    Brussels, Belgium · Recruiting

  • Be-Charleroi-GHDC

    Charleroi, Belgium · Recruiting

  • BE-Geel-STDIMPNA

    Geel, Belgium · Recruiting

  • BE-Gent-UZGENT

    Ghent, Belgium · Recruiting

  • BE-Hasselt-VIRGAJESSE (Jessa Ziekenhuis)

    Hasselt, Belgium · Recruiting

  • BE-Haine-Saint-Paul-JOLIMONT

    Jolimont, Belgium · Recruiting

  • BE-Leuven-UZLEUVEN

    Leuven, Belgium · Recruiting

  • BE-Liege-CHULIEGE

    Liège, Belgium · Recruiting

  • BE-Liege-MONTLEGIA

    Liège, Belgium · Recruiting

  • BE-Yvoir-MONTGODINNE

    Yvoir, Belgium · Recruiting

Showing 40 of 108 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.